Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives
US8673916B2 · kind B2 · utility
6Cited by
25References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 3, 2011 |
| Grant date | Mar 18, 2014 |
| Priority date | — |
| Expiry date | Aug 3, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to methods of treating disorders mediated by Histamine H3 receptors by administering novel pyridazinone derivatives. In particular, the pyridazinone compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.